Entrada Therapeutics (TRDA) Return on Sales (2023 - 2026)

Entrada Therapeutics' Return on Sales history runs 4 years deep, the most recent figure standing at 0.45% for Q1 2026.

• On a quarterly basis, Return on Sales fell 45.0% year-over-year to 0.45% in Q1 2026; TTM through Mar 2026 was 0.29%, a 29.0% decrease from a year earlier, with the FY2025 full-year figure at 0.06%, down 6.0% from the prior year.
• Return on Sales declined to 0.45% in Q1 2026 per TRDA's latest filing, from 0.3% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q3 2023 and bottomed at 0.45% in Q1 2026.
• The 4-year median for Return on Sales is 0.01% (2024), against an average of 0.1%.
• Across the five-year window, Return on Sales climbed 2 bps in 2024 and sank 45 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.0% in 2023, then jumped by 113 bps to 0.0% in 2024, then tumbled by 99813 bps to 0.3% in 2025, then sank by 51 bps to 0.45% in 2026.
• Per Business Quant, the three latest TRDA Return on Sales figures stand at 0.45% (Q1 2026), 0.3% (Q4 2025), and 0.27% (Q3 2025).